ZM008

ZM008 is a first-in-class, fully human IgG1 monoclonal antibody developed by Zumutor Biologics that targets LLT1 (CLEC2D) and disrupts the LLT1-CD161 interaction between natural killer (NK) cells and tumor cells. By blocking this pathway, ZM008 activates NK cells and subsequently T cells, leading to enhanced immune cell infiltration in the tumor microenvironment (TME), increased cytokine secretion, granzyme B/perforin release, and direct tumor cytotoxicity. The drug is designed to convert "cold" or less immune-responsive tumors into "hot" or highly immune-responsive tumors. It is being developed as monotherapy or in combination with Pembrolizumab for advanced solid tumors including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), prostate cancer, colorectal cancer (CRC), high-grade serous ovarian cancer (HGSOC), urothelial cancers, and others. It is manufactured by Catalent.